10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-SKP2 Antibody
Catalog # ABO10565

Specification

Anti-SKP2 Antibody - Product Information

Application	**WB, IHC**
Primary Accession	Q13309
Host	**Rabbit**
Reactivity	**Human, Mouse, Rat**
Clonality	**Polyclonal**
Format	**Lyophilized**

Description
Rabbit IgG polyclonal antibody for S-phase kinase-associated protein 2(SKP2) detection. Tested with WB, IHC-P in Human;Mouse;Rat.

Reconstitution
Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

Anti-SKP2 Antibody - Additional Information

Gene ID 6502

Other Names
S-phase kinase-associated protein 2, Cyclin-A/CDK2-associated protein p45, F-box protein Skp2, F-box/LRR-repeat protein 1, p45skp2, SKP2, FBXL1

Calculated MW
47761 MW KDa

Application Details
Immunohistochemistry(Paraffin-embedded Section), 0.5-1 µg/ml, Human, Rat, Mouse, By Heat
Western blot, 0.1-0.5 µg/ml, Human, Rat, Mouse

Subcellular Localization
Cytoplasm . Nucleus .

Protein Name
S-phase kinase-associated protein 2

Contents
Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.

Immunogen
A synthetic peptide corresponding to a sequence at the N-terminus of human SKP2(2-20aa HRKHLQEIPDLSSNVATSF), different from the related rat and mouse sequences by three amino acids.

Purification
Immunogen affinity purified.

Cross Reactivity
No cross reactivity with other proteins

Storage

At -20˚C for one year. After r˚Constitution, at 4˚C for one month. It˚Can also be aliquotted and stored frozen at -20˚C for a longer time.Avoid repeated freezing and thawing.

Sequence Similarities
Contains 1 F-box domain.

Anti-SKP2 Antibody - Protein Information

Name SKP2

Synonyms FBXL1

Function
Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins involved in cell cycle progression, signal transduction and transcription (PubMed:11931757, PubMed:12435635, PubMed:12769844, PubMed:12840033, PubMed:15342634, PubMed:15668399, PubMed:15949444, PubMed:16103164, PubMed:16262255, PubMed:16581786, PubMed:16951159, PubMed:17908926, PubMed:17962192, PubMed:22464731, PubMed:22770219, PubMed:32267835). Specifically recognizes phosphorylated CDKN1B/p27kip and is involved in regulation of G1/S transition (By similarity). Degradation of CDKN1B/p27kip also requires CKS1 (By similarity). Recognizes target proteins ORC1, CDT1, RBL2, KMT2A/MLL1, CDK9, RAG2, NBN, FOXO1, UBP43, YTHDF2, and probably MYC, TOB1 and TAL1 (PubMed:11931757, PubMed:12435635, PubMed:12769844, PubMed:12840033, PubMed:15342634, PubMed:15668399, PubMed:15949444, PubMed:16103164, PubMed:16581786, PubMed:16951159, PubMed:17908926, PubMed:17962192, PubMed:22464731, PubMed:32267835). Degradation of TAL1 also requires STUB1 (PubMed:<a

href="http://www.uniprot.org/citations/17962192" target="_blank">17962192). Recognizes CDKN1A in association with CCNE1 or CCNE2 and CDK2 (PubMed:16262255). Promotes ubiquitination and destruction of CDH1 in a CK1-dependent manner, thereby regulating cell migration (PubMed:22770219). Following phosphorylation in response to DNA damage, mediates 'Lys-63'-linked ubiquitination of NBN, promoting ATM recruitment to DNA damage sites and DNA repair via homologous recombination (PubMed:22464731).

Cellular Location
Cytoplasm. Nucleus

Anti-SKP2 Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Anti-SKP2 Antibody - Images



Anti-SKP2 antibody, ABO10565, Western blottingWB: MCF-7 Cell Lysate

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999



Anti-SKP2 antibody, ABO10565, IHC(P)IHC(P): Human Mammary Cancer Tissue

Anti-SKP2 Antibody - Background

The F box protein Skp2(S-phase kinase-associated protein 2) is oncogenic, and its frequent amplification and overexpression correlate with the grade of malignancy of certain tumors. Skp2 controls p300-p53 signaling pathways in cancer cells, making it a potential molecular target for cancer therapy. This gene positively regulates the G(1)-S transition by controlling the stability of several G(1) regulators, such as the cell cycle inhibitor p27. This study provides evidence of a role for an F-box protein in oncogenesis and establishes SKP2 as a protooncogene causally involved in the pathogenesis of lymphomas.